ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Dr Pantziarka talks to ecancertv about the work and aims of the ReDO project, which looks at the repurposing of drugs, often generics, which are not conventionally used for the treatment of cancer but have demonstrated potential anti-cancer properties.
Read Dr Pantziarka's research articles on the ReDO project for free - here and here.
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC
The Southeast Asian Breast Cancer Symposium; background, aims and successes
OncoAlert Round Up for August 4th - 10th, 2023
The current status of multiple myeloma diagnosis and treatment
Choosing Wisely in radiology Tanzania
TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer
Tusamitamab ravtansine combined with SoC shows encouraging anti-tumour activity for patients with nonsquamous NSCLC
Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours